Drug Trial Radar · NCT00066690
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,066
Actual
Start
Dec 17, 2003
Primary completion
May 2014
Study completion Nov 6, 2024
Sponsor
- Lead sponsor
- ETOP IBCSG Partners FoundationResearch network
- Sponsor type
- Research network
- Collaborators
- Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; SWOG Cancer Research Network
- First posted
- Aug 7, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.
Conditions
- Estrogen Receptor Positive Breast Cancer
- Progesterone Receptor Positive Tumor
- Recurrent Breast Carcinoma
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage IIIA Breast Cancer
Interventions
ExemestaneDrug
Exemestane 25mg orally daily for 5 years plus ovarian function suppression
Laboratory Biomarker AnalysisOther
Correlative studies
OophorectomyProcedure
Undergo bilateral surgical oophorectomy
Quality-of-Life AssessmentOther
Ancillary studies
Radiation TherapyRadiation
Undergo ovarian irradiation
TamoxifenDrug
Tamoxifen 20mg orally daily for 5 years
TriptorelinDrug
3.75 mg by im injection q28 days for 5 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free SurvivalTime frame: 5-year estimates, reported at a median follow-up of 67 months.
Locations
500 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Mayo Clinic in Arizona
Scottsdale, Arizona
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Mills - Peninsula Hospitals
Burlingame, California
East Bay Radiation Oncology Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
John Muir Medical Center-Concord Campus
Concord, California
Bay Area Breast Surgeons Inc
Emeryville, California
Kaiser Permanente-Fremont
Fremont, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
Glendale Memorial Hospital and Health Center
Glendale, California
Marin General Hospital
Greenbrae, California
Scripps Cancer Center
La Jolla, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California
Contra Costa Regional Medical Center
Martinez, California
Memorial Medical Center
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Bay Area Tumor Institute
Oakland, California
Hematology and Oncology Associates-Oakland
Oakland, California
Tom K Lee Inc
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute
Palo Alto, California
Valley Medical Oncology Consultants
Pleasanton, California
Eisenhower Medical Center
Rancho Mirage, California
Mercy Regional Cancer Center
Redding, California
Kaiser Permanente-Redwood City
Redwood City, California
Kaiser Permanente-Richmond
Richmond, California
Kaiser Permanente-Roseville
Roseville, California
Mercy General Hospital
Sacramento, California
Kaiser Permanente-South Sacramento
Sacramento, California
Kaiser Permanente - Sacramento
Sacramento, California
Salinas Valley Memorial
Salinas, California
University of California San Diego
San Diego, California
Kaiser Permanente-San Diego Mission
San Diego, California
Veterans Administration-San Diego Medical Center
San Diego, California
San Francisco General Hospital
San Francisco, California
Showing 40 of 500 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.